Study on survodutide for reducing protein in urine in kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether survodutide, an injected medication, can lower the amount of protein in your urine—a key sign of kidney damage. It's for people with chronic kidney disease who are already on standard blood pressure medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your kidney function is moderately reduced (measured by a blood test called eGFR between 20 and 90).
- You have protein in your urine (urine albumin-to-creatinine ratio above 30 and below 3500 mg/g).
- Your body mass index (BMI) is above 21 (weight in kg divided by height in meters squared).
- Your kidney function has been stable for the past 3 months (no big drops).
- You are already taking a stable dose of blood pressure medicines called ACE inhibitors or ARBs for at least 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medicine called HS-10390 can slow kidney disease and reduce protein leaking into urine in people with moderate kidney damage. You must already be taking blood pressure medications (ACE inhibitors or ARBs) to qualify.
This trial tests whether a new drug called SAL0140 can help people with chronic kidney disease who have protein leaking into their urine. The study will look at different doses to find the safest and most effective amount.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
This study tests an investigational injection called UBT251 for people with chronic kidney disease who are overweight. It aims to see if it can reduce protein in the urine and help protect kidney function.
This study tests HRS-7535, a new oral tablet that may help protect kidneys in people with chronic kidney disease. GLP-1 medications were originally developed for diabetes but may also benefit kidney function and overall health.
This study tests a new drug called LC-Z300-01 to see if it can reduce protein in the urine of people with type 2 diabetes and diabetic kidney disease. If you have diabetic kidney disease and are already on standard kidney-protective medications, this trial may offer a potential new treatment option.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.